Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
Disney Plans TV Restructuring With Hundreds of Layoffs 
Circle Urges EU to Revise MiCA Stablecoin Rules 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for DaVita investors under the federal securities laws.
To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
